Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra Approximately Four Years Earlier

Trial Profile

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra Approximately Four Years Earlier

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Meningococcal vaccine groups A B C Y W-135 conjugate (Primary)
  • Indications Meningococcal infections
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 01 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jan 2016 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 23 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top